Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 Shares

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the sale, the chief executive officer now owns 195,307 shares of the company’s stock, valued at approximately $8,708,739.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dominick Colangelo also recently made the following trade(s):

• On Wednesday, March 13th, Dominick Colangelo sold 17,500 shares of Vericel stock. The stock was sold at an average price of $44.67, for a total value of $781,725.00.

Vericel Trading Down 0.3 %

NASDAQ:VCEL opened at $43.74 on Friday. Vericel Co. has a 1 year low of $29.24 and a 1 year high of $53.05. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -486.00 and a beta of 1.71. The stock has a 50-day moving average price of $47.58 and a two-hundred day moving average price of $40.37.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.08. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The firm had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $64.28 million. During the same period in the previous year, the firm earned $0.12 earnings per share. The company’s revenue was up 23.3% on a year-over-year basis. Sell-side analysts forecast that Vericel Co. will post 0.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VCEL has been the subject of a number of recent research reports. Truist Financial restated a “buy” rating and set a $54.00 target price on shares of Vericel in a research report on Tuesday, March 26th. HC Wainwright upped their price objective on Vericel from $46.00 to $53.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, TheStreet upgraded Vericel from a “d+” rating to a “c-” rating in a report on Monday, January 29th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VCEL. MCF Advisors LLC boosted its position in shares of Vericel by 86.1% during the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after buying an additional 223 shares during the period. Gamco Investors INC. ET AL boosted its position in shares of Vericel by 1.9% during the second quarter. Gamco Investors INC. ET AL now owns 17,510 shares of the biotechnology company’s stock worth $658,000 after buying an additional 325 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Vericel by 8.1% during the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company’s stock worth $154,000 after buying an additional 344 shares during the period. LPL Financial LLC boosted its position in shares of Vericel by 6.6% during the second quarter. LPL Financial LLC now owns 8,348 shares of the biotechnology company’s stock worth $314,000 after buying an additional 518 shares during the period. Finally, Gotham Asset Management LLC boosted its position in shares of Vericel by 3.6% during the third quarter. Gotham Asset Management LLC now owns 15,311 shares of the biotechnology company’s stock worth $513,000 after buying an additional 538 shares during the period.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.